Critical role for BRCA1 expression as a marker of chemosensitivity response and prognosis.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Frontiers in Bioscience

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 26709647
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy

  2014cited by this paper
• BRCA1 mRNA Expression as a Predictive and Prognostic Marker in Advanced Esophageal Squamous Cell Carcinoma Treated with Cisplatin- or Docetaxel-Based Chemotherapy/Chemoradiotherapy

  2013cited by this paper
• BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma

  2013cited by this paper
• Methylation of BRCA1 Promoter Region Is Associated with Unfavorable Prognosis in Women with Early-Stage Breast Cancer

  2013cited by this paper
• miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.

  2013cited by this paper
• The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.

  2013cited by this paper
• Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.

  2013influential reference
• Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

  2013cited by this paper
• Prognostic significance of BRCA1 expression in gastric cancer

  2013cited by this paper
• BRCA1 Immunohistochemical Staining as a Prognostic Indicator in Uterine Serous Carcinoma

  2013cited by this paper
• BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study

  2013cited by this paper
• BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC

  2013cited by this paper
• Poly(ADP-ribose) polymerase inhibitors as cancer therapy.

  2013cited by this paper
• Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis

  2013cited by this paper
• Breast cancer patients with hypermethylation in the promoter of BRCA1 gene exhibit favorable clinical status.

  2012cited by this paper
• BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression

  2012cited by this paper
• Germline BRCA1 mutations increase prostate cancer risk

  2012cited by this paper
• BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer

  2012influential reference
• BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.

  2012cited by this paper
• Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

  2011cited by this paper
• Drug therapy for hereditary cancers

  2011cited by this paper
• Uterine Papillary Serous Carcinoma

  2011cited by this paper
• BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.

  2011cited by this paper
• Time to Think Outside the (Genetic) Box

  2011cited by this paper
• BRCA1 Loss Induces GADD153-Mediated Doxorubicin Resistance in Prostate Cancer

  2011cited by this paper
• Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer.

  2010cited by this paper
• Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer

  2010cited by this paper
• BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors.

  2010cited by this paper
• BRCA1/2 Germline Mutations in Jewish Patients With Uterine Serous Carcinoma

  2010cited by this paper
• Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer

  2010cited by this paper
• BRCA Germline Mutations in Women With Uterine Serous Carcinoma-Still a Debate

  2009cited by this paper
• Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations

  2009cited by this paper
• Familial Breast Cancer: Clinical Response to Induction Chemotherapy or Radiotherapy Related to BRCA1/2 Mutations Status

  2009cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Taxanes, microtubules and chemoresistant breast cancer.

  2008cited by this paper
• Decreased BRCA1 Confers Tamoxifen Resistance in Breast Cancer Cells by Altering Estrogen Receptor-Coregulator Interactions

  2008cited by this paper
• Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations.

  2008cited by this paper
• ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

  2008cited by this paper
• Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.

  2008cited by this paper
• BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer

  2007cited by this paper
• The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study.

  2007cited by this paper
• Common Variation in the BRCA1 Gene and Prostate Cancer Risk

  2007cited by this paper
• A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship.

  2007cited by this paper
• Role played by BRCA1 in transcriptional regulation in response to therapy.

  2007cited by this paper
• BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy

  2007cited by this paper
• The role of BRCA1 in transcriptional regulation and cell cycle control

  2006cited by this paper
• BRCA1 Downregulation Leads to Premature Inactivation of Spindle Checkpoint and Confers Paclitaxel Resistance

  2006cited by this paper
• Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes.

  2006cited by this paper
• High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.

  2006cited by this paper
• Options available for profiling small samples: a review of sample amplification technology when combined with microarray profiling

  2006cited by this paper
• BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• BRCA1 Interacts with and Is Required for Paclitaxel-Induced Activation of Mitogen-Activated Protein Kinase Kinase Kinase 3

  2004cited by this paper
• Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients

  2004cited by this paper
• MYC Is Amplified in BRCA1-Associated Breast Cancers

  2004cited by this paper
• BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.

  2004cited by this paper
• Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.

  2004cited by this paper
• Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2

  2003cited by this paper
• BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.

  2003cited by this paper
• BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells

  2003cited by this paper
• Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites.

  2003cited by this paper
• A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment

  2003cited by this paper
• Improved survival in women with BRCA‐associated ovarian carcinoma

  2003cited by this paper
• Transactivation of Repair Genes by BRCA1

  2002cited by this paper
• Cancer Incidence in BRCA1 mutation carriers.

  2002cited by this paper
• A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer

  2002cited by this paper
• Frequency of BRCA1 dysfunction in ovarian cancer.

  2002cited by this paper
• Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway

  2001cited by this paper
• Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.

  2000cited by this paper
• The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin*

  2000cited by this paper
• Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics

  1999cited by this paper
• Brca1 controls homology-directed DNA repair.

  1999cited by this paper
• BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).

  1998cited by this paper
• A targeted disruption of the murine Brca1 gene causes γ-irradiation hypersensitivity and genetic instability

  1998cited by this paper
• Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region

  1998cited by this paper
• BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins

  1998cited by this paper
• Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells

  1998cited by this paper
• Uterine papillary serous carcinoma. A clinical study

  1995cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper
• ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy

  1969cited by this paper

• Case Report: Influence of BRCA1 germline mutation on treatment-related morbidity of a non-seminomatous germ cell tumor patient

  2025cites this paper
• Radiosensitizing effect of a novel CTSS inhibitor by enhancing BRCA1 protein stability in triple‐negative breast cancer cells

  2024cites this paper
• Potential diagnostic and prognostic biomarkers for breast cancer: A compiled review.

  2023cites this paper
• Exploring diverse programmed cell-death patterns to develop a novel gene signature for predicting the prognosis of lung adenocarcinoma patients

  2023cites this paper
• Mechanistic insights into the survival curve of HeLa cells with a short shoulder and their S phase-specific sensitivity

  2023cites this paper
• Personalized Prescription of Chemotherapy Based on Assessment of mRNA Expression of BRCA1, RRM1, ERCC1, TOP1, TOP2α, TUBβ3, TYMS, and GSTP1 Genes in Tumors Compared to Standard Chemotherapy in the Treatment of Non-Small-Cell Lung Cancer

  2022cites this paper
• BRCA1 deficiency in triple-negative breast cancer: Protein stability as a basis for therapy.

  2022cites this paper
• BRCA1 Is a Novel Prognostic Indicator and Associates with Immune Cell Infiltration in Hepatocellular Carcinoma

  2020cites this paper
• Inhibition of c‐MET increases the antitumour activity of PARP inhibitors in gastric cancer models

  2020cites this paper
• Oxidative DNA Damage Modulates DNA Methylation Pattern in Human Breast Cancer 1 (BRCA1) Gene via the Crosstalk between DNA Polymerase β and a de novo DNA Methyltransferase

  2020cites this paper
• Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer

  2018cites this paper
• Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines

  2017cites this paper
• Prediction of therapy response in ovarian cancer: Where are we now?

  2017cites this paper